Using C-reactive protein to albumin ratio to predict heart events in acute coronary syndrome
Official title: Prediction of Acute Coronary Syndrome In-hospital Major Adverse Cardiovascular Events by High Sensitivity C- Reactive Protein to Albumin Ratio
Run by Sohag University · NCT06673381 · Data updated 2026-11-12
This study is testing if a blood test measuring the C-reactive protein to albumin ratio can help predict serious heart problems in patients with acute coronary syndrome while they are in the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | November 1, 2024 |
| Study ends | October 1, 2025 |
| Registry record updated | November 4, 2024 |
| Trial ID | NCT06673381 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with acute coronary syndrome who are not candidates for primary percutaneous coronary intervention.
✕Probably not a fit
Patients under 18, those with severe chronic conditions, or recent infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study assesses the predictive value of the high sensitive C-reactive protein to albumin ratio (hs-CAR) for in-hospital short-term major adverse cardiac events (MACEs) in patients with acute coronary syndrome (ACS). Conducted at the coronary care unit of Sohag University Hospital, the study includes patients diagnosed with ACS based on established guidelines. Blood samples are collected upon admission to measure hs-CRP and serum albumin levels, allowing for the calculation of hs-CAR and classification of patients into high and low hs-CAR groups. The primary endpoint is the occurrence of in-hospital MACEs, which include serious cardiac complications.
Why it matters
Potential benefit: If successful, this study could improve the prediction of serious cardiac events in ACS patients, potentially leading to better management and outcomes.
How similar studies have gone: While the specific approach of using hs-CAR in this context may be novel, similar studies have explored biomarkers for predicting cardiac events with varying degrees of success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients aged 18 Year or older presented by ACS not candidet for primary percutaneus coronary intervention ( PCI ) . Exclusion Criteria: * • Patients aged \< 18 years old * Patients who have eGFR \<60 ml/kg /m2 * Patients who have malignancies * Patients who have chronic heart failure (NYHA class \>II) * Pateints who have chronic liver disease * Patients who have nephrotic syndrome * Patients who have acute cerebrovascular stroke * Pregnant women * Patients who have recent infection
Where it's running
-
Sohag faculty of medicine
Sohag, Egypt Recruiting
Study contacts
- Principal investigator: Amira Elbasuony, resident — Sohag University
- Study coordinator: Amira Elbasuony, resident
- Email: amiraelbadawy518@gmail.com
- Phone: 01113695925
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Common femoral vein-to-artery diameter ratio to detect elevated LVEDP
Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.
-
Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure
This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.
-
Digital lifestyle platform after rehabilitation to support self-management
A digital, patient-facing platform is being tested to see if people who recently finished inpatient rehabilitation will use it and benefit from personalized lifestyle guidance at home.
-
AI-driven Medipixel fractional flow reserve to guide PCI
This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.
-
Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions
This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.
-
AI-assisted interpretation of chest pain CT in the emergency department
A pragmatic randomized trial tests whether an AI tool (Angiomics) helps emergency physicians interpret coronary CT angiography in adults with acute chest pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.